16th Nov 2026 09:57
(Alliance News) - AstraZeneca PLC on Monday announced that Alexion's Klygefa treatment received approval in both the US and EU for adults with generalised myasthenia gravis, a rare autoimmune disorder that causes severe muscle weakness.
The Cambridge, England-based pharmaceutical company said the approvals were based on positive results from the phase 3 Prevail trial. It showed clinical improvement as early as week one, compared to placebo.
Klygefa is an inhibitor that binds to the C5 protein in the terminal complement cascade, a part of the body's immune system. AstraZeneca explains: "When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. Klygefa's concurrent binding to serum albumin provides an extended half-life, enabling once-weekly dosing."
Marc Dunoyer, chief executive officer at Alexion, AstraZeneca's rare disease division, said: "The US approval of Klygefa delivers a first-of-its-kind treatment for gMG that offers the efficacy of C5 inhibition with the flexibility of once-weekly subcutaneous self-administration via autoinjector. We are proud to have discovered and developed this novel dual-binding nanobody, and look forward to soon delivering this pioneering innovation to adults with gMG in the US, offering the established efficacy and safety of C5 inhibition with added convenience."
Dunoyer added that the approval in the EU marked an "important milestone" for the gMG community.
Separately on Friday, AstraZeneca said cancer treatment Imfinzi was approved in the US for use in a perioperative regimen with enfortumab vedotin in patients with muscle-invasive bladder cancer.
The approval followed results from the phase III Volga trial, which showed a 49% reduction in the risk of recurrence, compared to radical cystectomy with or without approved adjuvant treatment.
Further, it demonstrated a 42% reduction in the risk of death, with a manageable safety profile.
AstraZeneca shares were 0.4% higher at 14,044.00 pence each on Monday morning in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca